Zobrazeno 1 - 10
of 57
pro vyhledávání: ''
Autor:
Xueping Chen, Ling Chen, Yue Wu, Yangli Zhang, Huili Bai, Xiaosong Li, Changlong He, Chengcheng Wei, Shi Chen, Jun Wen, Yifan Shen
Publikováno v:
Journal of Cancer Research and Clinical Oncology
Background By comparing the detection rate and type of targeted gene mutations in non-small cell lung cancer (NSCLC) between amplification refractory mutation system PCR (ARMS-PCR) and next-generation sequencing (NGS), the characteristics and applica
Autor:
Christoph Röcken, HM Behrens, F. W. Schäfer, L.-J. Kramp, M. van Mackelenbergh, Micaela Mathiak
Publikováno v:
Journal of Cancer Research and Clinical Oncology
Background We explored the hypothesis that high-quality standards in diagnostic mammography can lead to an early diagnosis of breast cancers and identifies at risk populations outside screening programs. The histopathological features and distributio
Autor:
Jan Budczies, Cornelius F. Waller, Amanda Tufman, Martina Kirchner, Torsten Goldmann, Albrecht Stenzinger, Peter Schirmacher, Petros Christopoulos, Michael Meister, Mark Kriegsmann, Michael Thomas, Martin Reck, Solange Peters, Klaus Kluck, Hauke Winter, Julia Glade, Daniel Kazdal, Stefan Fröhling, Michael Allgäuer, Thomas Muley, Felix J.F. Herth, CP Heußel, Martin Wermke
Publikováno v:
Cancer Immunology, Immunotherapy
Introduction The advent of immune checkpoint blockade (ICB) has led to significantly improved disease outcome in lung adenocarcinoma (ADC), but response of ALK/EGFR-positive tumors to immune therapy is limited. The underlying immune biology is incomp
Autor:
Eiji Takeuchi, Hisanori Machida, Naoki Kadota, Tsutomu Shinohara, Keishi Naruse, Yoshio Okano, Nobuo Hatakeyama, Yoshihiro Kondou, Katsuhiro Atagi
Publikováno v:
Cancer Immunology, Immunotherapy
Objective Tumor-related eosinophilia may have extended survival benefits for some cancer patients. However, there has been no report on the prognosis difference between eosinophilic pleural effusion (EPE) and non-EPE in lung cancer patients. Our stud
Autor:
Georg Hutarew, Barbara Zellinger, Peter A Winkler, Dorothee Hölzl, Hans U Schlicker, Karl Sotlar, Theo Kraus, Christoph Schwartz
Publikováno v:
Journal of Cancer Research and Clinical Oncology
Purpose Gliomas are the most frequent primary brain tumors of adults. Despite intensive research, there are still no targeted therapies available. Here, we performed an integrated analysis of glioma and programmed cell death ligand 1 (PD-L1) in 90 sa
Autor:
Bijan Zomorodbakhsch, Jutta Hübner, Andreas Hochhaus, Matthias Rengsberger, Tobias Rachow, Thomas Ernst, Michael Hartmann, Clemens P J G Wolf, Susan Foller
Publikováno v:
Journal of Cancer Research and Clinical Oncology
Purpose The aim of our study was to analyse the frequency and severity of different types of potential interactions in oncological outpatients’ therapy. Therefore, medications, food and substances in terms of complementary and alternative medicine
Publikováno v:
Journal of Cancer Research and Clinical Oncology
Purpose Advances in testicular cancer screening and therapy increased 10-year survival to 97% despite a rising incidence; eventually expanding the population of survivors requiring follow-up. We analyzed 10-year follow-up costs after testicular cance
Autor:
William Rodin, Filip Ahlmanner, Elinor Bexe Lindskog, Yvonne Wettergren, Louis Szeponik, Kamil Kajetan Zajt, Marianne Quiding Järbrink, Patrik Sundström
Publikováno v:
Cancer Immunology, Immunotherapy
Mucosal-associated invariant T (MAIT) cells are unconventional T cells recognizing microbial metabolites, presented by the invariant MR1 protein. Upon activation, MAIT cells rapidly secrete cytokines and exert cytotoxic functions, and may thus be hig
Autor:
Masanori Hayashi, Tetsuro Yamagishi, Chihaya Imai, Hajime Umezu, Takashi Ariizumi, Yudai Murayama, Akira Ogose, Naoki Oike, Hiroyuki Kawashima, Hiroshi Hatano, Naoto Endo
Publikováno v:
Cancer Immunology, Immunotherapy
The characteristics of the tumor immune microenvironment remains unclear in liposarcomas, and here we aimed to determine the prognostic impact of the tumor immune microenvironment across separate liposarcomas subtypes. A total of 70 liposarcoma patie
Autor:
Zhefeng Liu, Shixue Chen, Jinliang Wang, Sujie Zhang, Junxun Ma, Zhaozhen Wu, Huang Di, Haitao Tao, Xuan Zheng, Yi Hu, Pengfei Cui, Xiao Wang, Ruixin Li, Ziwei Huang
Publikováno v:
Cancer Immunology, Immunotherapy
Background Rationale exists for combining immune checkpoint inhibitors and PARP inhibitors (PARPi), and results of clinical trials in ovarian cancer are promising, but data in other cancers are limited. Method Efficacy and safety of PARPi/anti-PD-1 i